Life Molecular Imaging and R2IBF Announce the First Commercial PET Scan of Florbetaben (18F) in Brazil
prweb.com
news
2022-05-31 13:30:00

Today, a comprehensive clinical evaluation in combination with in-vivo biomarkers, such as beta-amyloid PET imaging, can improve the diagnostic accuracy, allowing for improved patient management and access to AD drug trials. BOSTON and SAO PAULO (PRWEB) May 31, 2022 Life Molecular Imaging in partnership with R2IBF are proud to announce that InsCer Diagnostic Center is the first center to perform a florbetaben (18F) PET scan in Brazil. Florbetaben (18F) is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.
